Recent in vitro studies have shown that increased expression of TFRC reduces non-small cell lung cancer (NSCLC) cell proliferation, demonstrating early potential for TFRC as a therapeutic target [58,59]. Here, TFRC is linked to non-small cell lung carcinoma.